Equities research analysts predict that Vericel Corp (NASDAQ:VCEL) will announce $24.30 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Vericel’s earnings, with estimates ranging from $24.10 million to $24.50 million. Vericel posted sales of $19.01 million during the same quarter last year, which suggests a positive year over year growth rate of 27.8%. The company is scheduled to announce its next earnings report on Monday, August 5th.
According to Zacks, analysts expect that Vericel will report full-year sales of $113.69 million for the current fiscal year, with estimates ranging from $113.48 million to $113.90 million. For the next fiscal year, analysts forecast that the business will report sales of $146.18 million, with estimates ranging from $141.85 million to $150.50 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow Vericel.
Vericel (NASDAQ:VCEL) last released its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.07) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.07). The business had revenue of $21.81 million during the quarter, compared to analysts’ expectations of $22.51 million. Vericel had a negative return on equity of 3.40% and a negative net margin of 3.51%. The company’s quarterly revenue was up 21.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.21) earnings per share.
A number of equities analysts have issued reports on the company. Zacks Investment Research cut Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, May 11th. BidaskClub upgraded Xilinx from a “hold” rating to a “buy” rating in a report on Saturday, June 29th. Finally, Oppenheimer lowered their target price on 2U from $83.00 to $67.00 and set an “outperform” rating for the company in a report on Wednesday, May 8th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $22.98.
In related news, CFO Gerard J. Michel sold 17,500 shares of Vericel stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $17.02, for a total transaction of $297,850.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Steven C. Gilman sold 7,500 shares of Vericel stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $16.81, for a total value of $126,075.00. The disclosure for this sale can be found here. Insiders sold a total of 59,500 shares of company stock valued at $1,031,835 in the last 90 days. 4.50% of the stock is owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. grew its holdings in Vericel by 3.5% during the fourth quarter. BlackRock Inc. now owns 2,966,530 shares of the biotechnology company’s stock worth $51,618,000 after purchasing an additional 100,687 shares during the period. RTW Investments LP grew its holdings in Vericel by 3.2% during the fourth quarter. RTW Investments LP now owns 2,289,134 shares of the biotechnology company’s stock worth $39,831,000 after purchasing an additional 71,218 shares during the period. Northern Trust Corp grew its holdings in Vericel by 1.5% during the fourth quarter. Northern Trust Corp now owns 550,249 shares of the biotechnology company’s stock worth $9,575,000 after purchasing an additional 8,260 shares during the period. Emerald Mutual Fund Advisers Trust grew its holdings in Vericel by 37.1% during the first quarter. Emerald Mutual Fund Advisers Trust now owns 548,360 shares of the biotechnology company’s stock worth $9,602,000 after purchasing an additional 148,360 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Vericel by 4.6% during the fourth quarter. Geode Capital Management LLC now owns 496,490 shares of the biotechnology company’s stock worth $8,638,000 after purchasing an additional 21,962 shares during the period. Institutional investors and hedge funds own 85.16% of the company’s stock.
VCEL stock traded down $0.03 during trading hours on Friday, reaching $19.42. 215,481 shares of the stock were exchanged, compared to its average volume of 606,694. The firm’s 50-day simple moving average is $17.58. The company has a market cap of $853.39 million, a P/E ratio of -138.71 and a beta of 2.83. The company has a debt-to-equity ratio of 0.24, a quick ratio of 8.16 and a current ratio of 8.47. Vericel has a 12 month low of $9.60 and a 12 month high of $21.00.
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns.
See Also: Range Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.